Skip to content

Richard Baird

  • MD, PhD
  • Academic Consultant in Experimental Cancer Therapeutics
  • University of Cambridge
  • 15h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1167CitationsNumber of citations received by Richard's publications. Updated daily.

Research interests

Breast cancer therapeuticsBiomarker developmentNew drug development


Dr. Richard Baird graduated with degrees in Social and Political Sciences (Cambridge University, 1994) and Medicine (London University, 1997). After gaining Membership of the Royal College of Physicians, he undertook a translational research fellowship in Professor Paul Workman's group at the Institute of Cancer Research before completing specialist training in Medical Oncology at the Royal Marsden Hospital in London and Surrey, UK. Dr. Baird gained valuable further experience in running early phase clinical trials during a Senior Clinical Research Training Fellowship at the Royal Marsden Drug Development Unit. In September 2011, Dr. Baird was appointed to a faculty position at the University of Cambridge, as Academic Consultant in Cancer Therapeutics. His interests include: phase 1 clinical trials of first-in-class, first-in-human anti-cancer drugs, studies combining targeted therapies, biomarker development and breast cancer therapeutics.

Co-authors (291)

Publications (5)

  • Bias in the recovery of circulating nucleic acids from body fluids and its implications for liquid biopsy

    • Hudecova I
    • Smith C
    • Heider K
    • et al.
  • Copy-number scores from shallow whole-genome sequencing are versatile quantitative markers in liquid biopsy

    • Chandrananda D
    • Mouliere F
    • Ahlborn L
    • et al.
  • OT1-03-02. MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors

    • Baird R
  • OT1-06-03. The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

    • Turner N
  • Perspectives in Gynecologic Oncology

    • Baird R
    • Van Hagen T
    Get full text

Professional experience

Academic Consultant in Experimental Cancer Therapeutics

University of Cambridge

June 2011 - Present

Senior Clinical Research Fellow, Drug Development Unit

Royal Marsden Hospital & Institute of Cancer Research

September 2009 - June 2011(2 years)

Specialist Registrar in Medical Oncology

Royal Marsden Hospital

September 2005 - August 2009(4 years)

Clinical Research Fellow

Institute of Cancer Research

February 2002 - August 2005(4 years)

Training in general (internal) medicine

Hospitals in London and SE England

August 1997 - February 2002(5 years)

Education history

MRCP, General (Internal) Medicine

Royal College of Physicians

April 2001

MBBS, Medicine

King's College Medical School

September 1994 - June 1997(3 years)

MA, Social and Political Science

University of Cambridge

October 1991 - June 1994(3 years)